CLEC12A/CLL-1 (E5T5V) Rabbit mAb #57950

Part of the NK gene complex, C-type lectin-like molecule 1 (MICL/DCAL-2/CLL-1/CLEC12A) encodes a type-II transmembrane glycoprotein whose expression is largely restricted to hematopoietic cells of the myeloid lineage such as monocytes, macrophages, dendritic cells, and neutrophils (1-3). Research studies have shown that CLL-1 possesses a single C-type lectin-like domain within the extracellular domain and a single ITIM motif within its short cytoplasmic tail, which facilitates association with inhibitory SH2 domain-containing tyrosine phosphatases, SHP-1 and SHP-2. It is thought that signaling through the ITIM motif of CLL-1 facilitates inhibition of myeloid cell activation (1,2). By serving as a receptor for DAMPs that become exposed on dead cells, such as uric acid crystals, CLL-1 restrains pro-inflammatory immune responses that occur in response to cell death (4). In addition to being expressed on normal differentiated myeloid cells, research studies have also demonstrated expression of CLL-1 on the surface of malignant myeloid cells (5). As a result, CLL-1 has received significant attention as a potential novel therapeutic target for AML as its expression is absent from normal hematopoietic stem cells but is highly overexpressed on AML stem cells (5-9).